Fundraising Fox
Aditum Bio
Venture capitalOperating companyOakland · Series A–Series B · 8 people tracked
Also known as ADITUM BIO MANAGEMENT COMPANY, LLC
Find your way into Aditum Bio
Sign up to see every warm intro you have to Aditum Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aditum Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Aditum Bio pursues an alternative, patient-driven model of drug development aimed at identifying promising, clinic-ready therapies for underserved patient populations in areas such as obesity, depression, substance abuse, renal disease, and infectious diseases. Many drug candidates go undeveloped due to strategic decisions and high clinical trial costs, and the firm seeks to fill that gap. Using in-house R&D domain experts as the foundation of an agile operating model, it accelerates the formation and ramp-up of portfolio companies, augmenting dedicated leadership teams with medical and scientific experts. The firm leverages technology and partnerships to execute clinical trials efficiently, advancing acquired drug candidates into Phase 2 more quickly and at lower cost.
Source: firm website, verified Sep 29, 2026.
Team · 8 people
from the firm's website & curated & public directories
What they invest in
from 6 of 8 portfolio companiesBiotech ×6Medical Devices ×5Digital Health ×3Healthtech ×2
HQs:United States×5
Investments · 8 tracked
founders shown can be your intro pathBy year:2025 · 12021 · 23 dated
Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Eli LillyDavid A. Ricks(Chair, President, and Chief Executive Officer)Lucas Montarce(Executive Vice President and Chief Financial Officer)Daniel M. Skovronsky(Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs)in
Co-investorsKleiner PerkinsMassChallenge MexicoMicron Ventures
Coastline Bio is a biopharmaceutical company developing novel medicines for immunological skin diseases, with an initial focus on atopic dermatitis.
BiotechHealthtechMedical DevicesOakland, US
Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections.
BiotechDigital HealthMedical DevicesOakland, US
Donald Ganem(Executive Officer, Director)Benjamine Liu(Director)Ilan Zipkin(Director)
Board seatJoseph Jimenez· per SEC Form D
Co-investorsPMV
Celexor Bio develops monoclonal antibody therapeutics targeting plasmacytoid dendritic cells to treat severe autoimmune and inflammatory disorders by interrupting the inflammatory cascade at its source.
BiotechDigital HealthMedical DevicesOakland, US
Kalexo Bio develops dual-targeting siRNA therapeutics for cardiovascular disease, with a focus on lipid management and atherosclerotic disease prevention.
BiotechDigital HealthMedical Devices
Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion.
BiotechHealthtechMedical DevicesLexington, US
Samantha Truex(Chief Executive Officer)in
Co-investorsGV (Google Ventures)
Co-investorsTCG CrossoverAtlas Venture
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
1 IPOsEli LillyNYSE: LLY
Portfolio news
latest coverage across their companies
Eli Lilly · pharmexec.com · Aug 30, 2026
Oblenio Bio · finsmes.com · Jun 25, 2026
Frequently asked questions
- How many investments has Aditum Bio made?
- Aditum Bio has 8 tracked investments, 1 of which have exited, including 1 dated in the last 24 months.
- What stage does Aditum Bio invest at?
- Aditum Bio invests at the Series A, Series B stages.
- What sectors does Aditum Bio focus on?
- Aditum Bio focuses on AI & Machine Learning, Biotech.
- Where is Aditum Bio located?
- Aditum Bio is headquartered in Oakland, US.
- Who does Aditum Bio co-invest with?
- Aditum Bio most often shares deals with GV (Google Ventures), Kleiner Perkins, MassChallenge Mexico, among 5 tracked co-investors.
Images
Co-investors · 1
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Firms observed investing alongside Aditum Bio, from public investor directories. Shared companies are the overlap with Aditum Bio's recorded portfolio.
Similar investors
Madrona Venture Group is a venture capital firm that backs founding teams at the seed, early, and acceleration stages, with a focus on Seattle, the Bay Area, and beyond.
Wing Venture Capital is an early-stage venture fund backing founders building the AI-first economy across infrastructure, enterprise, physical, domain-specific, security, and healthcare AI.
OneVentures is a later-stage venture capital firm that backs technology and healthcare companies, providing growth equity and credit alongside strategic and operational support.
Quadrille is an independent investment manager focused on venture capital and growth equity, investing globally in technology and healthcare assets.
ACME Capital is a venture firm that backs deep-tech founders combining technical ambition with decisive execution, supporting companies through every phase of growth.